Condition: MSI-H/dMMR Solid Tumors · Sponsor: BeiGene
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
This description comes directly from the study's public registry record.
BeiGene · +1-877-828-5568 · clinicaltrials@beigene.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Completed |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Completed |
| The Affiliated Hospital of Military Medical Sciences | Beijing, Beijing Municipality, China | Completed |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Active Not Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Active Not Recruiting |
| Guangdong Provincial Peoples Hospital | Guangzhou, Guangdong, China | Completed |
| Nanfang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Completed |
| The Sixth Affiliated Hospital, Sun Yat Sen University | Guangzhou, Guangdong, China | Completed |
| Huizhou First Hospital | Huizhou, Guangdong, China | Recruiting |
| Meizhou People Hospital | Meizhou, Guangdong, China | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03736889